BAMLET administration via drinking water inhibits intestinal tumor development and promotes long-term health

Thi Hien Tran, Murphy Wan, Ines Ambite, Michele Cavalera, Mario Grossi, Jaromir Háček, Parisa Esmaeili, António N B M Carneiro, Arunima Chaudhuri, Shahram Ahmadi, Catharina Svanborg

Research output: Contribution to journalArticlepeer-review

13 Downloads (Pure)

Abstract

Though new targeted therapies for colorectal cancer, which progresses from local intestinal tumors to metastatic disease, are being developed, tumor specificity remains an important problem, and side effects a major concern. Here, we show that the protein-fatty acid complex BAMLET (bovine alpha-lactalbumin made lethal to tumor cells) can act as a peroral treatment for colorectal cancer. ApcMin/+ mice, which carry mutations relevant to hereditary and sporadic human colorectal cancer, that received BAMLET in the drinking water showed long-term protection against tumor development and decreased expression of tumor growth-, migration-, metastasis- and angiogenesis-related genes. BAMLET treatment via drinking water inhibited the Wnt/β-catenin and PD-1 signaling pathways and prolonged survival without evidence of toxicity. Systemic disease in the lungs, livers, spleens, and kidneys, which accompanied tumor progression, was inhibited by BAMLET treatment. The metabolic response to BAMLET included carbohydrate and lipid metabolism, which were inhibited in tumor prone ApcMin/+ mice and weakly regulated in C57BL/6 mice, suggesting potential health benefits of peroral BAMLET administration in addition to the potent antitumor effects. Together, these findings suggest that BAMLET administration in the drinking water maintains antitumor pressure by removing emergent cancer cells and reprogramming gene expression in intestinal and extra-intestinal tissues.
Original languageEnglish
Article number3838
Number of pages21
JournalScientific Reports
Volume14
DOIs
Publication statusPublished - 15 Feb 2024

Cite this